Immunocore

Biotech & Life Sciences · Milton, United Kingdom · Founded 2008 · IPO 2021

TCR bispecific immunotherapies for cancer and infectious diseases

Valuation $1.31B

Revenue $448M

Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Talent graph

Immunocore's talent

Book a demo to see the people

Employees mapped 607 incl. 2 AI specialists

Founders /100 quality score

Key operators 10 quality /100

Potential founders likely future founders

Startup mafia 5 alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

12 investors on Immunocore's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage

Eli Lilly

Woodford Investment Management

RTW Investments

Series B+ 9 investors entered at this stage

JDRF T1D Fund

Rock Springs Capital

General Atlantic

WuXi Healthcare Ventures

BlackRock

Bill & Melinda Gates Foundation

CCB International

Omega Funds

University of Oxford

Immunocore mafia

Startups founded by Immunocore alumni

Former Immunocore employees who went on to start their own companies. Sorted by Dealroom signal score.

Yellowstone BiosciencesEst. 2023

Julian HirstUnited Kingdom

Signal score81

AdaptimmuneEst. 2008

Bent JakobsenUnited Kingdom

Signal score64

Zelluna ImmunotherapyEst. 2016

NHNamir HassanNorway

Signal score59

invIOsEst. 2022

PLPeter Llewellyn-DaviesAustria

Signal score56

Ducentis BioTherapeuticsEst. 2015

RARebecca AshfieldUnited Kingdom

Signal score47

Book a demo to explore the full alumni network →

Global footprint

Where Immunocore has talent and traffic

Workforce by country

8 countries with
team presence

🇬🇧 United Kingdom65.3%

🇺🇸 United States32.5%

🇮🇪 Ireland0.9%

🇪🇸 Spain0.4%

🇨🇭 Switzerland0.2%

Top 5 of 8 shown

Web traffic by country

14K monthly visits
across markets

🇺🇸 United States60.7%

🇬🇧 United Kingdom22.9%

🇯🇵 Japan7.1%

🇮🇳 India7.1%

🇵🇭 Philippines0.7%

Top 5 markets shown

Patent intelligence

$101M patent portfolio · 54 active families

Estimated portfolio value

$101M

7.7% of market cap · 7.8× smaller than top peer BioNTech ($788M)

54 active patent families

Where Immunocore innovates Alpha chainCancer researchCarcinosisCell biologyCellular receptor

Where Immunocore concentrates vs peers

Each axis is a top-10 topic across Immunocore and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Immunocore

An AI-synthesized read of the highest-engagement posts about Immunocore on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Immunocore on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles